Not surprisingly, co-treatment of LY294002 (PI3K inhibitor) along with C75 reduced both eIF4B as well as USP11 in GC-DLBCL (Supplementary Figure 32B). Here, USP11 is linked to diffuse large B-cell lymphoma.